

ADMISSION OF THE MAUNA KEA TECHNOLOGIES SHARE TO THE SRD "LONG"

PARIS, February 7, 2012 - Mauna Kea Technologies (NYSE Euronext: MKEA, FR0010609263), leader in the endomicroscopy market, today announces the upcoming admission of its share to the "SRD Long-Only" of the Deferred Settlement Service.

Admission was granted following the quarterly revision of the NYSE Euronext Paris indices and as a result of the share's daily liquidity of over 100,000 euros. A regulated market service, the SRD "long-only" will enable investors to take long positions while buying shares or credit. Admission of the Mauna Kea Technologies share to the SRD "long-only" will take place at the opening of the stock market session February 24, 2012.

"We are delighted to be joining the SRD Deferred Settlement Service which will provide Mauna Kea Technologies' shares with better visibility and liquidity less than eight months after its first listing. This decision will allow a new category of investors to position themselves on the share," said Sacha Loiseau, founder and CEO of Mauna Kea Technologies. "On behalf of the entire team, I would like to take this opportunity to thank all of our shareholders for their interest in the Company."

About Mauna Kea Technologies

Mauna Kea Technologies is a global medical device company and leader in the endomicroscopy market. The company researches, develops and markets innovative tools to visualize and detect abnormalities in the gastro-intestinal and pulmonary tracts. Its flagship product, Cellvizio®, a probe-based Confocal Laser Endomicroscopy (pCLE) system, provides physicians and researchers high-resolution cellular views of tissue inside the body. Large, international, multi-center clinical trials have demonstrated Cellvizio's ability to help physicians more accurately detect early forms of disease and make treatment decisions immediately. Designed to improve patient outcomes and reduce costs within a hospital, Cellvizio can be used with almost any endoscope. Cellvizio has 510(k) clearance from the U.S. Food and Drug Administration and the European CE-Mark for use in the GI and pulmonary tracts.

For more information about Mauna Kea Technologies, go to www.maunakeatech.com

United States

Lazar Partners Ltd.

Erich Sandoval

Tel: +1 917 497 2867

esandoval@lazarpartners.com

Mauna Kea Technologies

Eric Cohen

Vice-President Finance

Tel: +33 (0) 1 70 08 09 70

investor-vpf@maunakeatech.com



France et Europe

ALIZE RP

Caroline Carmagnol

Tel: +33 (0)1 42 68 86 43 / +33 (0)6 64 18 99 59

caroline@alizerp.com

Anne –Sophie Cosquéric

Tel: +33 (0)1 42 68 86 41

anne-sophie@alizerp.com

NewCap.

Investor Relations and Financial Communication

Pierre Laurent / Florent Alba

Tel: +33(0)1 44 71 94 94

maunakea@newcap.fr